Epidemiology of candidemia at a children;s hospital, 2002 to 2006

Pediatric Infectious Disease Journal

Volumn 28, Issue 9, 2009, Pages 806-809

  Neu, Natalie ^a,f   Malik, Mariam ^b   Lunding, Amy ^c   Whittier, Susan ^d   Alba, Luis ^a   Kubin, Christine ^e   Saiman, Lisa ^a,d  

^a NewYork Presbyterian Hospital   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Surgeons Columbia University ^*  (United States)

^d NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f MPH   (United States)

Author keywords

Antifungal susceptibility; Candida species; Pediatric candidemia

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDEMIA; CHILD; COMORBIDITY; DEMOGRAPHY; DRUG USE; ELECTRONIC MEDICAL RECORD; FEMALE; FUNGUS ISOLATION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PEDIATRIC HOSPITAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 70249138029     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181a0d78d     Document Type: Article

References (32)

1. Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis. 2003;37:634-643.
2. Zaoutis TE, Greves HM, Lautenbach E, et al. Risk factors for disseminated candidiasis in children with candidemia. Pediatr Infect Dis J. 2004;23:635-641.
3. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309-317.
4. Benjamin DK Jr, Stoll BJ, Fanaroff AA, et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics. 2006;117:84-92.
5. Cotten CM, McDonald S, Stoll B, et al. The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics. 2006;118:717-722.
6. Feja KN, Wu F, Roberts K, et al. Risk factors for candidemia in critically ill infants: a matched case-control study. J Pediatr. 2005;147:156-161.
7. Trick WE, Fridkin SK, Edwards JR, et al. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis. 2002;35:627-630.
8. Gualco L, Debbia EA, Bandettini R, et al. Antifungal resistance in Candida spp. isolated in Italy between 2002 and 2005 from children and adults. Int J Antimicrob Agents. 2007;29:179-184.
9. Pfaller MA, Diekema DJ, Jones RN, et al. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol. 2002;40:852-856.
10. Singhi SC, Reddy TC, Chakrabarti A. Candidemia in a pediatric intensive care unit. Pediatr Crit Care Med. 2004;5:369-374.
11. Chen YC, Chang SC, Luh KT, et al. Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years. J Antimicrob Chemother. 2003;52:71-77.
12. Marco F, Danes C, Almela M, et al. Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidula-fungin, of Candida bloodstream isolates. Results from a six-year study (1996-2001). Diagn Microbiol Infect Dis. 2003;46:259-264.
13. Diekema DJ, Messer SA, Brueggemann AB, et al. Epidemiology of can-didemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol. 2002;40:1298-1302.
14. Manzoni P, Stolfi I, Pugni L, et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med. 2007;356: 2483-2495.
15. Weitkamp JH, Ozdas A, Lafleur B, et al. Fluconazole prophylaxis for prevention of invasive fungal infections in targeted highest risk preterm infants limits drug exposure. J Perinatol. 2008;28:405-411.
16. Huang YC, Kao HT, Lin TY, et al. Antifungal susceptibility testing and the correlation with clinical outcome in neonatal candidemia. Am J Perinatol. 2001;18:141-146.
17. Wong-Beringer A, Kriengkauykiat J. Systemic antifungal therapy: new options, new challenges. Pharmacotherapy. 2003;23:1441-1462.
18. Safdar A, Perlin DS, Armstrong D. Hematogenous infections due to Candida parapsilosis: changing trends in fungemic patients at a comprehensive cancer center during the last four decades. Diagn Microbiol Infect Dis. 2002;44:11-16.
19. Lagrou K, Verhaegen J, Peetermans WE, et al. Fungemia at a tertiary care hospital: incidence, therapy, and distribution and antifungal susceptibility of causative species. Eur J Clin Microbiol Infect Dis. 2007;26:541-547.
20. CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Third Informational Supplement. 3rd ed. Villanova, PA: Clinical and Laboratory Standards Institute; 2008
21. CLSI Document M27-A3. NCCLS. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. 2nd ed. Villanova, PA: Clinical and Laboratory Standards Institute; 2002. NCCLS Document M27-A2
22. Goulet O, Ruemmele F. Causes and management of intestinal failure in children. Gastroenterology. 2006;130(suppl 1):S16-S28. (Pubitemid 43208856)
23. Thompson JS. Overview of etiology and management of intestinal failure. Gastroenterology. 2006;130(suppl 1):S3-S4.
24. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis. 2003;3:685-702.
25. Rangel-Frausto MS, Wiblin T, Blumberg HM, et al. National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis. 1999;29:253-258.
26. Fridkin SK, Kaufman D, Edwards JR, et al. Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995- 2004. Pediatrics. 2006;117:1680-1687.
27. Stamos JK, Rowley AH. Candidemia in a pediatric population. Clin Infect Dis. 1995;20:571-575.
28. Saiman L, Ludington E, Pfaller M, et al. Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J. 2000;19:319-324.
29. Singhi S, Rao DS, Chakrabarti A. Candida colonization and candidemia in a pediatric intensive care unit. Pediatr Crit Care Med. 2008;9:91-95.
30. Manzoni P, Farina D, Galletto P, et al. Type and number of sites colonized by fungi and risk of progression to invasive fungal infection in preterm neonates in neonatal intensive care unit. J Perinat Med. 2007;35:220-226.
31. Sofair AN, Lyon GM, Huie-White S, et al. Epidemiology of community-onset candidemia in Connecticut and Maryland. Clin Infect Dis. 2006;43: 32-39.
32. Manzoni P, Leonessa M, Galletto P, et al. Routine use of fluconazole prophylaxis in a neonatal intensive care unit does not select natively fluconazole-resistant Candida subspecies. Pediatr Infect Dis J. 2008;27: 731-737